Large Trial of Intranasal Oxytocin for Autism Shows Mixed Results but Hints at Benefit for Repetitive Behaviors
A 106-person randomized trial found intranasal oxytocin did not improve core social symptoms of autism over placebo, but significantly reduced repetitive behaviors and increased social gaze fixation.
Quick Facts
What This Study Found
No between-group difference on the primary endpoint (ADOS reciprocity, effect size -0.08, P=.69), but oxytocin significantly reduced repetitive behavior (effect size 0.44, P=.026) and increased gaze fixation on social regions (effect size 0.55, P=.018).
Key Numbers
106 participants; 48 IU/day intranasal oxytocin; 6-week duration; no significant difference on primary social reciprocity outcome.
How They Did This
Randomized, parallel-group, multicenter, placebo-controlled, double-blind trial in Japan. 106 ASD adults (18-48 y.o.) received 6 weeks of intranasal oxytocin (48 IU/day) or placebo. Measured ADOS scores and eye-tracking gaze patterns.
Why This Research Matters
This is the first large-scale, rigorous trial of oxytocin for autism. While the primary endpoint was negative, the significant effects on repetitive behavior and social gaze suggest oxytocin may have specific benefits that could be optimized with different dosing, duration, or combination approaches.
The Bigger Picture
Small studies had generated enthusiasm about oxytocin for autism, but this well-designed trial tempers expectations for broad social symptom improvement. The specific benefits for repetitive behavior and social gaze may guide future research toward more targeted applications or combination therapies.
What This Study Doesn't Tell Us
Strong placebo response on primary endpoint may have masked real effects. 6-week duration may be too short. Dose of 48 IU/day may not be optimal. Only adult males with high-functioning ASD were included, limiting generalizability.
Questions This Raises
- ?Would longer treatment duration or higher doses of oxytocin produce more robust social improvements?
- ?Could oxytocin combined with behavioral therapy enhance social outcomes beyond either alone?
- ?Do the benefits for repetitive behaviors and social gaze translate to meaningful improvements in daily functioning?
Trust & Context
- Key Stat:
- 106 participants largest randomized controlled trial of oxytocin for autism spectrum disorder
- Evidence Grade:
- High-quality RCT with proper blinding and multicenter design. Negative primary outcome but significant secondary findings provide nuanced evidence.
- Study Age:
- Published in 2020. Oxytocin for ASD remains an active research area with ongoing trials exploring different approaches.
- Original Title:
- Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.
- Published In:
- Molecular psychiatry, 25(8), 1849-1858 (2020)
- Authors:
- Yamasue, Hidenori(4), Okada, Takashi(2), Munesue, Toshio(3), Kuroda, Miho, Fujioka, Toru, Uno, Yota, Matsumoto, Kaori, Kuwabara, Hitoshi, Mori, Daisuke, Okamoto, Yuko, Yoshimura, Yuko, Kawakubo, Yuki, Arioka, Yuko, Kojima, Masaki, Yuhi, Teruko, Owada, Keiho, Yassin, Walid, Kushima, Itaru, Benner, Seico, Ogawa, Nanayo, Eriguchi, Yosuke, Kawano, Naoko, Uemura, Yukari, Yamamoto, Maeri, Kano, Yukiko, Kasai, Kiyoto, Higashida, Haruhiro, Ozaki, Norio, Kosaka, Hirotaka
- Database ID:
- RPEP-05211
Evidence Hierarchy
Frequently Asked Questions
Why might oxytocin help with autism?
Oxytocin is often called the 'social hormone' because it naturally promotes bonding, trust, and social awareness. Since autism involves challenges with social interaction, boosting oxytocin levels could theoretically help.
Why did both groups improve?
The strong placebo response is common in autism trials — participants may improve simply from the extra attention and structure of being in a clinical trial, making it harder to detect drug effects.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05211APA
Yamasue, Hidenori; Okada, Takashi; Munesue, Toshio; Kuroda, Miho; Fujioka, Toru; Uno, Yota; Matsumoto, Kaori; Kuwabara, Hitoshi; Mori, Daisuke; Okamoto, Yuko; Yoshimura, Yuko; Kawakubo, Yuki; Arioka, Yuko; Kojima, Masaki; Yuhi, Teruko; Owada, Keiho; Yassin, Walid; Kushima, Itaru; Benner, Seico; Ogawa, Nanayo; Eriguchi, Yosuke; Kawano, Naoko; Uemura, Yukari; Yamamoto, Maeri; Kano, Yukiko; Kasai, Kiyoto; Higashida, Haruhiro; Ozaki, Norio; Kosaka, Hirotaka. (2020). Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.. Molecular psychiatry, 25(8), 1849-1858. https://doi.org/10.1038/s41380-018-0097-2
MLA
Yamasue, Hidenori, et al. "Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.." Molecular psychiatry, 2020. https://doi.org/10.1038/s41380-018-0097-2
RethinkPeptides
RethinkPeptides Research Database. "Effect of intranasal oxytocin on the core social symptoms of..." RPEP-05211. Retrieved from https://rethinkpeptides.com/research/yamasue-2020-effect-of-intranasal-oxytocin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.